These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23869491)

  • 1. Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes.
    Kulasekararaj AG; Mohamedali AM; Mufti GJ
    Br J Haematol; 2013 Sep; 162(5):587-605. PubMed ID: 23869491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
    Nakajima H
    Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetics of MDS.
    Ogawa S
    Blood; 2019 Mar; 133(10):1049-1059. PubMed ID: 30670442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetics of myelodysplastic syndromes: new insights.
    Graubert T; Walter MJ
    Hematology Am Soc Hematol Educ Program; 2011; 2011():543-9. PubMed ID: 22160087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.
    Zhang L; Padron E; Lancet J
    Leuk Res; 2015 Jan; 39(1):6-17. PubMed ID: 25465125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies.
    Ronaghy A; Yang RK; Khoury JD; Kanagal-Shamanna R
    Curr Hematol Malig Rep; 2020 Jun; 15(3):194-202. PubMed ID: 32382988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic basis of myelodysplastic syndromes.
    Ogawa S
    Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(3):107-121. PubMed ID: 32161209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genetic basis of myelodysplastic syndromes.
    Bejar R; Ebert BL
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):295-315. PubMed ID: 20359627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of somatic panels for the detection of haematopoietic transformation in children and young adults with leukaemia predisposition syndromes and with acquired cytopenias.
    Noy-Lotan S; Krasnov T; Dgany O; Jeison M; Yanir AD; Gilad O; Toledano H; Barzilai-Birenboim S; Yacobovich J; Izraeli S; Tamary H; Steinberg-Shemer O
    Br J Haematol; 2021 May; 193(3):570-580. PubMed ID: 33368157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The functional mechanisms of mutations in myelodysplastic syndrome.
    Nagata Y; Maciejewski JP
    Leukemia; 2019 Dec; 33(12):2779-2794. PubMed ID: 31673113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.
    Neukirchen J; Lauseker M; Hildebrandt B; Nolting AC; Kaivers J; Kobbe G; Gattermann N; Haas R; Germing U
    Cancer; 2017 Dec; 123(23):4608-4616. PubMed ID: 28746789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic abnormalities and pathophysiology of MDS.
    Hosono N
    Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genomic aberrations in myelodysplastic syndromes and related disorders].
    Makishima H
    Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathophysiology of MDS: genomic aberrations].
    Ichikawa M
    Rinsho Ketsueki; 2016; 57(10):1972-1979. PubMed ID: 27725595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling.
    Flach J; Dicker F; Schnittger S; Schindela S; Kohlmann A; Haferlach T; Kern W; Haferlach C
    Leukemia; 2011 Apr; 25(4):713-8. PubMed ID: 21233836
    [No Abstract]   [Full Text] [Related]  

  • 18. Lack of nucleophosmin mutation in patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
    Shiseki M; Kitagawa Y; Wang YH; Yoshinaga K; Kondo T; Kuroiwa H; Okada M; Mori N; Motoji T
    Leuk Lymphoma; 2007 Nov; 48(11):2141-4. PubMed ID: 17990177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
    Jiang Y; Dunbar A; Gondek LP; Mohan S; Rataul M; O'Keefe C; Sekeres M; Saunthararajah Y; Maciejewski JP
    Blood; 2009 Feb; 113(6):1315-25. PubMed ID: 18832655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia.
    Liao R; Xu Y; Chen M; Chen X; Zhan X; Sun J
    Hematology; 2013 Jul; 18(4):191-7. PubMed ID: 23321417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.